Wells Fargo & Company Fennec Pharmaceuticals Inc. Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 6,019 shares of FENC stock, worth $36,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,019

Previous 5,224 15.22%

Holding current value

$36,294

Previous $58,000 13.79%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$8.82 - $11.12 $7,011 - $8,840	795 Added 15.22%	6,019 $66,000
Q4 2023 Feb 09, 2024	BUY	$6.48 - $11.61 $7,050 - $12,631	1,088 Added 26.31%	5,224 $58,000
Q3 2023 Nov 13, 2023	SELL	$7.15 - $8.94 $20,120 - $25,157	-2,814 Reduced 40.49%	4,136 $31,000
Q2 2023 Aug 15, 2023	BUY	$7.27 - $9.82 $48,301 - $65,244	6,644 Added 2171.24%	6,950 $61,000
Q1 2023 May 12, 2023	BUY	$7.38 - $10.35 $2,258 - $3,167	306 New	306 $2,000

Q4 2021 Feb 14, 2022	SELL	$3.89 - $10.01 $5,446 - $14,014	-1,400 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.96 - $7.85 $1.1 Million - $1.45 Million	-184,509 Reduced 99.25%	1,400 $10,000
Q1 2021 May 13, 2021	BUY	$6.21 - $8.68 $813,143 - $1.14 Million	130,941 Added 238.21%	185,909 $1.16 Million
Q4 2020 Feb 09, 2021	BUY	$5.99 - $8.55 $24,690 - $35,243	4,122 Added 8.11%	54,968 $409,000
Q3 2020 Nov 05, 2020	BUY	$5.19 - $10.17 $197,723 - $387,446	38,097 Added 298.82%	50,846 $308,000
Q2 2020 Aug 13, 2020	BUY	$5.43 - $9.39 $59,453 - $102,811	10,949 Added 608.28%	12,749 $106,000
Q1 2020 May 14, 2020	BUY	$4.89 - $8.1 $8,802 - $14,580	1,800 New	1,800 $11,000

Others Institutions Holding FENC

# of Institutions

Shares Held

14.4M

Call Options Held

53.2K

Put Options Held

83.9K

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $157M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Fennec Pharmaceuticals Inc. Transaction History